Churg-Strauss syndrome risk factors: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Churg-Strauss syndrome}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References==...") |
No edit summary |
||
| (21 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Churg-Strauss syndrome}} | {{Churg-Strauss syndrome}} | ||
{{CMG}}; {{AE}}{{CK}} | |||
==Overview== | |||
There are no established risk factors for [[eosinophilic granulomatosis with polyangiitis]]. However, certain environmental agents including various [[Allergen|allergens]], [[Infection|infections]], [[Desensitization (medicine)|desensitization]], [[vaccination]], and [[genetics]] may act as triggering agents. Those triggers may be responsible for the [[Inflammation|inflammatory response]] with [[Eosinophil granulocyte|eosinophils]] and [[Lymphocyte|lymphocytes]] and [[Macrophage|macrophages]]. | |||
==Risk Factors== | |||
*Various environmental agents including various [[Allergen|allergens]], [[Infection|infections]], [[Desensitization (medicine)|desensitization]], [[vaccination]], and [[genetics]] may act as triggering agents. These triggers may be responsible for the [[Inflammation|inflammatory response]] with [[Eosinophil granulocyte|eosinophils]] and [[Lymphocyte|lymphocytes]] leading to [[vasculitis]] and [[necrosis]]. | |||
==Common Risk Factors== | |||
Common [[Risk factor|risk factors]] in the development of [[eosinophilic granulomatosis with polyangiitis]] may be various [[Allergen|allergens]], [[Infection|infections]], [[Genetics|genetic factors]], and desensitization to [[:Category:Drugs|drugs]] and [[Vaccination|vaccinations.]] | |||
*Genetic determinants:<ref name="pmid17763415">{{cite journal |vauthors=Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A, Garini G, Manganelli P, Bottero P, Tumiati B, Sinico RA, Savi M, Buzio C, Neri TM |title=HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome |journal=Arthritis Rheum. |volume=56 |issue=9 |pages=3159–66 |date=September 2007 |pmid=17763415 |doi=10.1002/art.22834 |url=}}</ref><ref name="pmid18512809">{{cite journal |vauthors=Wieczorek S, Hellmich B, Arning L, Moosig F, Lamprecht P, Gross WL, Epplen JT |title=Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis |journal=Arthritis Rheum. |volume=58 |issue=6 |pages=1839–48 |date=June 2008 |pmid=18512809 |doi=10.1002/art.23496 |url=}}</ref> | |||
**[[Human leukocyte antigen|HLA]]-DRB1*04 AND *07 | |||
**[[HLA-DRB4]] | |||
**[[Interleukin 10]] gene [[Single nucleotide polymorphism|single nucleotide polymorphisms]] | |||
*[[Allergy|Allergic agents]] | |||
*[[Infection|Infections]] | |||
*[[Vaccination]] | |||
*Exposure to [[Silicon dioxide|silica]]<ref name="pmid23820041">{{cite journal |vauthors=Gómez-Puerta JA, Gedmintas L, Costenbader KH |title=The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis |journal=Autoimmun Rev |volume=12 |issue=12 |pages=1129–35 |date=October 2013 |pmid=23820041 |pmc=4086751 |doi=10.1016/j.autrev.2013.06.016 |url=}}</ref> | |||
*[[:Category:Drugs|Drugs]]:<ref name="pmid18549941">{{cite journal |vauthors=Puéchal X, Rivereau P, Vinchon F |title=Churg-Strauss syndrome associated with omalizumab |journal=Eur. J. Intern. Med. |volume=19 |issue=5 |pages=364–6 |date=July 2008 |pmid=18549941 |doi=10.1016/j.ejim.2007.09.001 |url=}}</ref><ref name="pmid8834352">{{cite journal |vauthors=Orriols R, Muñoz X, Ferrer J, Huget P, Morell F |title=Cocaine-induced Churg-Strauss vasculitis |journal=Eur. Respir. J. |volume=9 |issue=1 |pages=175–7 |date=January 1996 |pmid=8834352 |doi= |url=}}</ref> | |||
**[[Leukotriene antagonist|Leukotriene receptor antagonists]]/ Leukotriene modifying agents (eg, [[montelukast]], [[zafirlukast]]) | |||
**Anti-IgE antibody (eg, [[omalizumab]]) | |||
**[[Cocaine]] | |||
**Inhaled [[glucocorticoids]] | |||
**[[Mesalazine]] | |||
**[[Propylthiouracil]] | |||
**[[Methimazole]] | |||
**[[Macrolide|Macrolides]] | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: (name of the system)]] | |||
Latest revision as of 17:52, 12 April 2018
|
Churg-Strauss syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Churg-Strauss syndrome risk factors On the Web |
|
American Roentgen Ray Society Images of Churg-Strauss syndrome risk factors |
|
Risk calculators and risk factors for Churg-Strauss syndrome risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [2]
Overview
There are no established risk factors for eosinophilic granulomatosis with polyangiitis. However, certain environmental agents including various allergens, infections, desensitization, vaccination, and genetics may act as triggering agents. Those triggers may be responsible for the inflammatory response with eosinophils and lymphocytes and macrophages.
Risk Factors
- Various environmental agents including various allergens, infections, desensitization, vaccination, and genetics may act as triggering agents. These triggers may be responsible for the inflammatory response with eosinophils and lymphocytes leading to vasculitis and necrosis.
Common Risk Factors
Common risk factors in the development of eosinophilic granulomatosis with polyangiitis may be various allergens, infections, genetic factors, and desensitization to drugs and vaccinations.
- Genetic determinants:[1][2]
- HLA-DRB1*04 AND *07
- HLA-DRB4
- Interleukin 10 gene single nucleotide polymorphisms
- Allergic agents
- Infections
- Vaccination
- Exposure to silica[3]
- Drugs:[4][5]
- Leukotriene receptor antagonists/ Leukotriene modifying agents (eg, montelukast, zafirlukast)
- Anti-IgE antibody (eg, omalizumab)
- Cocaine
- Inhaled glucocorticoids
- Mesalazine
- Propylthiouracil
- Methimazole
- Macrolides
References
- ↑ Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A, Garini G, Manganelli P, Bottero P, Tumiati B, Sinico RA, Savi M, Buzio C, Neri TM (September 2007). "HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome". Arthritis Rheum. 56 (9): 3159–66. doi:10.1002/art.22834. PMID 17763415.
- ↑ Wieczorek S, Hellmich B, Arning L, Moosig F, Lamprecht P, Gross WL, Epplen JT (June 2008). "Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis". Arthritis Rheum. 58 (6): 1839–48. doi:10.1002/art.23496. PMID 18512809.
- ↑ Gómez-Puerta JA, Gedmintas L, Costenbader KH (October 2013). "The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis". Autoimmun Rev. 12 (12): 1129–35. doi:10.1016/j.autrev.2013.06.016. PMC 4086751. PMID 23820041.
- ↑ Puéchal X, Rivereau P, Vinchon F (July 2008). "Churg-Strauss syndrome associated with omalizumab". Eur. J. Intern. Med. 19 (5): 364–6. doi:10.1016/j.ejim.2007.09.001. PMID 18549941.
- ↑ Orriols R, Muñoz X, Ferrer J, Huget P, Morell F (January 1996). "Cocaine-induced Churg-Strauss vasculitis". Eur. Respir. J. 9 (1): 175–7. PMID 8834352.